Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books for Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR). Prof. Sarfraz Ahmad is Director of Clinical Research at Gynecologic Oncology Program of AdventHealth Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD in Biochemistry from North-Eastern Hill University, Shillong. Prof. Ahmad’s research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology, hematology, and gastroenterology patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic/hematologic disorders. Prof. Ahmad has published over 275 peer-reviewed scholarly research articles and book chapters, and over 400 scientific abstracts. He is a reviewer and has editorial responsibilities for several biomedical journals and books; and has received competitive research grants and national/international awards for his research contributions/accomplishments

• 1. Clinical and safety assessment of the HCC patients2. Liver transplantation for HCC therapy3. Clinical trials for HCC in the diagnosis and therapy: An international perspective4. Recent advancements in immunotherapy interventions for the management of HCC5. Role of genetic insights and tumor microenvironment in HCC: New opportunities for gene therapy6. An Update on the treatment of hepatocellular carcinoma7. An update of image-based surveillance in HCC8. Meta-analysis of PD-1/PD-L1 inhibitors in advanced HCC9. Towards a personalized medicine approach for the treatment of HCC10. Precision medicine in the theranostics of HCC11. Immunohistology of HCC-enabled precision medicine12. Artificial Intelligence and Precision Medicine for HCC13. Genomics-Enabled Precision Medicine for HCC

Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books for Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR). Prof. Sarfraz Ahmad is Director of Clinical Research at Gynecologic Oncology Program of AdventHealth Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD in Biochemistry from North-Eastern Hill University, Shillong. Prof. Ahmad’s research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology, hematology, and gastroenterology patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic/hematologic disorders. Prof. Ahmad has published over 275 peer-reviewed scholarly research articles and book chapters, and over 400 scientific abstracts. He is a reviewer and has editorial responsibilities for several biomedical journals and books; and has received competitive research grants and national/international awards for his research contributions/accomplishments

• 1. Clinical and safety assessment of the HCC patients2. Liver transplantation for HCC therapy3. Clinical trials for HCC in the diagnosis and therapy: An international perspective4. Recent advancements in immunotherapy interventions for the management of HCC5. Role of genetic insights and tumor microenvironment in HCC: New opportunities for gene therapy6. An Update on the treatment of hepatocellular carcinoma7. An update of image-based surveillance in HCC8. Meta-analysis of PD-1/PD-L1 inhibitors in advanced HCC9. Towards a personalized medicine approach for the treatment of HCC10. Precision medicine in the theranostics of HCC11. Immunohistology of HCC-enabled precision medicine12. Artificial Intelligence and Precision Medicine for HCC13. Genomics-Enabled Precision Medicine for HCC

Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books for Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR). Prof. Sarfraz Ahmad is Director of Clinical Research at Gynecologic Oncology Program of AdventHealth Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD in Biochemistry from North-Eastern Hill University, Shillong. Prof. Ahmad’s research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology, hematology, and gastroenterology patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic/hematologic disorders. Prof. Ahmad has published over 275 peer-reviewed scholarly research articles and book chapters, and over 400 scientific abstracts. He is a reviewer and has editorial responsibilities for several biomedical journals and books; and has received competitive research grants and national/international awards for his research contributions/accomplishments

• 1. Clinical and safety assessment of the HCC patients2. Liver transplantation for HCC therapy3. Clinical trials for HCC in the diagnosis and therapy: An international perspective4. Recent advancements in immunotherapy interventions for the management of HCC5. Role of genetic insights and tumor microenvironment in HCC: New opportunities for gene therapy6. An Update on the treatment of hepatocellular carcinoma7. An update of image-based surveillance in HCC8. Meta-analysis of PD-1/PD-L1 inhibitors in advanced HCC9. Towards a personalized medicine approach for the treatment of HCC10. Precision medicine in the theranostics of HCC11. Immunohistology of HCC-enabled precision medicine12. Artificial Intelligence and Precision Medicine for HCC13. Genomics-Enabled Precision Medicine for HCC